Trials / Completed
CompletedNCT00269516
SLV308 for Treatment of Patients With Early Parkinson's Disease
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 468 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pardoprunox | fixed dose 6 mg |
| DRUG | Pardoprunox | fixed dose 12 mg |
| DRUG | Pardoprunox | 12-42mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-12-23
- Last updated
- 2008-08-29
Locations
128 sites across 21 countries: United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russia, Serbia, Slovakia, South Africa, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT00269516. Inclusion in this directory is not an endorsement.